PhotoPharmics recently said it received FDA breakthrough device designation for noninvasive Specialized Phototherapy Device to treat Parkinson’s disease.
The device is administered through a prescription from a doctor and is an adjunct therapy for treating Parkinson’s disease, according to the company. It is designed to be used with standard dopaminergic therapy and can be used at home.
“Very few device companies receive the breakthrough designation. Our device is the first specialized phototherapy device ever to achieve this status,” CEO Kent Savage said in a news release. “We believe this is largely due to the improvements we saw in non-motor symptoms. Since there is no known cure for Parkinson’s disease, our mission is to help people recover function and return to what they enjoy doing most. This recognition by FDA validates our work.”
The company is currently financing a pivotal, phase 3 study of the device through a Series B round and plans to recruit for the study starting in August this year.
"device" - Google News
May 04, 2020 at 09:37PM
https://ift.tt/2W1kPiP
PhotoPharmics wins FDA breakthrough device designation for noninvasive Parkinson's treatment device - Mass Device
"device" - Google News
https://ift.tt/2KSbrrl
https://ift.tt/2YsSbsy
Bagikan Berita Ini
0 Response to "PhotoPharmics wins FDA breakthrough device designation for noninvasive Parkinson's treatment device - Mass Device"
Post a Comment